Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961041 | 0.80 | HTT (0.46) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL8910598 | 0.80 | GAA (0.52) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL13636390 | 0.80 | GAA (0.52) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL12741450 | 0.80 | ESR1 (0.54) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL10874676 | 0.80 | ESR1 (0.54) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL16563870 | 0.80 | ESR1 (0.54) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL1546559 | 0.78 | GAA (0.50) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL1186120 | 0.78 | GAA (0.51) | HTTKDM4EALDH1A1MAPTGAA | |
| SCHEMBL2777133 | 0.78 | GAA (0.50) | HTTKDM4EGAAKMT2AMEN1 | |
| SCHEMBL1186121 | 0.78 | GAA (0.51) | HTTKDM4EALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141672-B2 | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147755-A1 | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2004-07-29 | — | — | US | disclosed |
| US-6699896-B1 | METABOLIC DISORDERS, ANTIDIABETIC AGENTS; OBESITY | WYETH | 2004-03-02 | — | — | US | disclosed |
| EP-1077966-B1 | BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | WYETH CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6310081-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6221902-B1 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147755-A1 | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, GCKR | HTT 3224/4885KDM4E 2775/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.